- Home
- ARQT vs DFIN Comparison
ARQT vs DFIN Comparison
Compare ARQT & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- DFIN
- Stock Information
- Founded
- ARQT 2016
- DFIN 1983
- Country
- ARQT United States
- DFIN United States
- Employees
- ARQT N/A
- DFIN N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- DFIN Other Consumer Services
- Sector
- ARQT Health Care
- DFIN Consumer Discretionary
- Exchange
- ARQT Nasdaq
- DFIN Nasdaq
- Market Cap
- ARQT 1.7B
- DFIN 1.8B
- IPO Year
- ARQT 2020
- DFIN N/A
- Fundamental
- Price
- ARQT $15.99
- DFIN $56.28
- Analyst Decision
- ARQT Strong Buy
- DFIN Strong Buy
- Analyst Count
- ARQT 7
- DFIN 3
- Target Price
- ARQT $19.00
- DFIN $68.67
- AVG Volume (30 Days)
- ARQT 1.8M
- DFIN 323.6K
- Earning Date
- ARQT 08-06-2025
- DFIN 07-31-2025
- Dividend Yield
- ARQT N/A
- DFIN N/A
- EPS Growth
- ARQT N/A
- DFIN N/A
- EPS
- ARQT N/A
- DFIN 2.79
- Revenue
- ARQT $263,464,999.00
- DFIN $755,000,000.00
- Revenue This Year
- ARQT $61.83
- DFIN $1.91
- Revenue Next Year
- ARQT $36.55
- DFIN $4.64
- P/E Ratio
- ARQT N/A
- DFIN $20.19
- Revenue Growth
- ARQT 99.50
- DFIN N/A
- 52 Week Low
- ARQT $8.03
- DFIN $37.80
- 52 Week High
- ARQT $17.75
- DFIN $70.55
- Technical
- Relative Strength Index (RSI)
- ARQT 56.88
- DFIN 49.34
- Support Level
- ARQT $15.43
- DFIN $53.83
- Resistance Level
- ARQT $17.29
- DFIN $55.43
- Average True Range (ATR)
- ARQT 0.97
- DFIN 1.72
- MACD
- ARQT 0.06
- DFIN 0.28
- Stochastic Oscillator
- ARQT 63.70
- DFIN 72.14
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.